Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek October 4, 2004 Gene G. Marcial	A New Owner For Aspect? Some pros say Aspect Medical Systems may be in play. Shares have leaped to $17, up from $13.
The Motley Fool November 22, 2005 Stephen D. Simpson	Cyberonics' Ride Not Over Yet One way or another, this medical device maker's stock is almost certain to produce more volatility in the years to come.
The Motley Fool May 4, 2006 Stephen D. Simpson	Aspect Won't Put You to Sleep High valuation of this med-tech company all but guarantees that the stock will see some volatility.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool June 24, 2009 Brian Orelli	Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well.
The Motley Fool September 26, 2005 Stephen D. Simpson	Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors?
CRM June 10, 2015	Fonolo and Aspect Partner to Bring Multichannel Call-Backs to Call Centers Fonolo joins the Aspect Technology Alliance Program.
The Motley Fool February 7, 2006 Stephen D. Simpson	Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again.
BusinessWeek December 6, 2004 Gene G. Marcial	Boston Scientific: Anemic -- For Now Boston Scientific is far from robust -- since its summer recall of 100,000 coronary stents and since its lowered fourth-quarter profit forecast. Analysts quickly cut estimates, driving shares down from 46 in May to 33.36 on Nov. 23.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
The Motley Fool February 3, 2011 Thomas Lee	Boston Scientific Wants to Be a Rock Star. But First, It Needs Some Stars Boston Scientific has been talking the talk of late. But its walk the past few years can be best described as a limp.
The Motley Fool May 25, 2005 Stephen D. Simpson	Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors.
The Motley Fool September 2, 2004 Tom Taulli	What's Next for Open Text? The company's quarter was fairly ugly. Then again, the enterprise software industry is becoming a killing ground for investors.
The Motley Fool January 17, 2006 Stephen D. Simpson	High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this.
The Motley Fool July 21, 2010 Brian Orelli	Boston Scientific Bounces When you're as beaten-down as Boston Scientific, you seemingly have nowhere to go but up. There's also bankruptcy, but the beleaguered medical device maker seems far from that -- at least for now.
The Motley Fool April 23, 2008 Brian Orelli	Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up.
The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
CRM March 14, 2014 Leonard Klie	Aspect Software Releases Workforce Optimization 8.0 and Aspect Mentor Aspect's WFO 8.0 and Aspect Mentor expand the reach of speech analytics beyond basic call recordings.
American Family Physician September 15, 2002	Depression What is depression?... What causes depression?... How is depression diagnosed?... How is depression treated?... What about suicide?...
The Motley Fool April 18, 2006 Stephen D. Simpson	Get Ready for the New Boston Scientific Here's hoping it does a better job as a bigger business. For all of the risks that are present, there still could be rewards here for investors.
BusinessWeek December 12, 2005 Gene G. Marcial	Why Spectranetics Is Special Tiny medical device maker Spectranetics has been a stock on the go.
The Motley Fool April 9, 2010 Brian Orelli	Is Boston Scientific Turning It Around? Selling off a pair of units could help.
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
The Motley Fool November 11, 2009 Jim Mueller	This Company Is a Value Stock! Isn't It? A look at Boston Scientific leads to conflicting conclusions.
The Motley Fool February 3, 2011 Brian Orelli	Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes.
The Motley Fool August 12, 2010 Brian Orelli	Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later.
American Family Physician October 15, 2006	Depression: What You Should Know A patient guide: What is depression?... What causes depression?... Symptoms of Depression... How is depression diagnosed?... etc.
The Motley Fool February 15, 2006 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's buying now? Boston Scientific... Franklin Bank... Fossil... Gartner... iPass...
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
InternetNews June 16, 2004 Paul Shread	Analyst Predicts Adobe Slowdown CS First Boston thinks Adobe's run may be about over.
Pharmaceutical Executive January 1, 2006 Michael Fronstin	A Fresh Look at Co-morbidity You may think you understand a disease. But then it arrives in tandem. A new survey takes a fresh look at co-morbidity.
The Motley Fool October 18, 2010 Anand Chokkavelu	There Are Better Opportunities Than Boston Scientific Let's take a look. By the numbers, Abbott, Medtronic, and Johnson & Johnson all look more compelling than Boston Scientific.
The Motley Fool February 12, 2010 Brian Orelli	Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.
American Family Physician September 15, 2002	Depression in Women Is depression common in women?... What are the symptoms?... What causes depression?... Symptoms of Depresssion... How is depression treated?... Are antidepressants safe for any woman with depression?... etc.
Wired May 19, 2008 Daniel Carlat	Brain Scans as Mind Readers? Don't Believe the Hype Can Spect scans of the brain really show our mind in action, or are we allowing ourselves to be seduced by images that may actually tell us very little?
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
Managed Care April 2006 Tony Berberabe	Insurers Rely on Providers To Screen for Depression With access only to claims data, health plans strive to promote the importance of depression screening to their providers.
BusinessWeek July 28, 2003 Gene G. Marcial	A Net Stock Rises from the Ashes Only the stout-hearted might want to touch shares of 24/7 Real Media, whose stock collapsed from a high of 64 in January, 1999, to 9 cents on Sept. 21, 2001. It has since bounced to 1.81 on July 16, 2003 -- thanks to the runup in tech and Internet stocks.